Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Zydus gets FDA nod for generic Ascorbic acid

22 August 2026 · By · Wire by Fusion42

Published

22 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at pharma.economictimes.indiatimes.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Zydus Lifesciences received US FDA approval for its generic ascorbic acid injection with 180 days of market exclusivity, targeting treatment of scurvy in patients over 5 months old. The product competes with McGuff Pharmaceuticals’ Ascor, which has $11.6 million in annual US sales, and will be manufactured in Gujarat, India.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You have a six-month window to establish your generic ascorbic acid in the US market before competitors enter. Prioritise partnerships with US distributors and healthcare providers to capture sales from McGuff Pharmaceuticals' customers.

◆ Coverage

1 source · 22 Aug 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalgeneric-drugascorbic-acidmarket-exclusivitypharmamanufacturing